Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months.
Gutiérrez-Tarango MD, Berber A. Gutiérrez-Tarango MD, et al. Among authors: berber a. Chest. 2001 Jun;119(6):1742-8. doi: 10.1378/chest.119.6.1742. Chest. 2001. PMID: 11399700 Clinical Trial.
They were randomized to receive either OM-85 BV or placebo (one capsule a day for 10 days a month for 3 consecutive months) at the beginning of the trial and 6 months later with the same schedule. ...The number of antibiotic courses was 2.46 +/- 2.08 (median, 1.5) i …
They were randomized to receive either OM-85 BV or placebo (one capsule a day for 10 days a month for 3 consecutive months) at …
Use of Broncho-Vaxom in private practice: phase IV trial in 587 children.
Berber AC, Del-Rio-Navarro BE. Berber AC, et al. Clin Ther. 1996 Nov-Dec;18(6):1068-79. doi: 10.1016/s0149-2918(96)80062-2. Clin Ther. 1996. PMID: 9001824 Clinical Trial.
We conducted a Phase IV, open-label clinical trial to test the efficacy and safety of the immunomodulating agent Broncho-Vaxom in private practice. The trial comprised 587 children younger than 12 years of age who had an acute respiratory tract infection at entry and a
We conducted a Phase IV, open-label clinical trial to test the efficacy and safety of the immunomodulating agent Broncho-Vaxom in pri …
[Efficacy of the immunoestimulant OM-BV85 in the Prevention of Respiratory Infections].
Del-Rio-Navarro B, Becerril-Ngeles M, Berber A. Del-Rio-Navarro B, et al. Among authors: berber a. Rev Alerg Mex. 2012 Jul-Sep;59(3):155-71. Rev Alerg Mex. 2012. PMID: 24007992 Spanish.
A recent study points to the utility of OM-BV85 in the treatment of children with wheezing secondary to repetitive respiratory infections. Although, there were immunostimulants with well defined mechanism of action in the future, currently OM-BV85 is a good option f
A recent study points to the utility of OM-BV85 in the treatment of children with wheezing secondary to repetitive respiratory infect
Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections (ARTIs) in children that attend day-care centers.
Berber A, Del-Rio-Navarro BE. Berber A, et al. Health Econ Rev. 2019 May 7;9(1):12. doi: 10.1186/s13561-019-0230-1. Health Econ Rev. 2019. PMID: 31065886 Free PMC article.
Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension.
Fanghänel G, Cortinas L, Sánchez-Reyes L, Gómez-Santos R, Campos-Franco E, Berber A. Fanghänel G, et al. Among authors: berber a. Adv Ther. 2003 Mar-Apr;20(2):101-13. doi: 10.1007/BF02850257. Adv Ther. 2003. PMID: 12836810 Clinical Trial.
Following a 2-week washout to confirm the diagnosis of hypertension, antihypertensive medication was adjusted to achieve a blood pressure less than 140/90 mm Hg before institution of either sibutramine 10 mg or placebo once a day. A body mass index in …
Following a 2-week washout to confirm the diagnosis of hypertension, antihypertensive medication was adjusted to achieve a blo …
Use of OM-85 BV for the prevention of acute respiratory tract infections in occupational medicine.
Carmona-Ramírez MA, Alvárez-Gómez V, Berber A. Carmona-Ramírez MA, et al. Among authors: berber a. J Int Med Res. 2002 May-Jun;30(3):325-9. doi: 10.1177/147323000203000316. J Int Med Res. 2002. PMID: 12166352 Clinical Trial.
The patients were followed for a further 9 months. Mean number of ARTIs decreased from 8.2 +/- 2.1 per worker in 1999 to 5.3 +/- 2.9 in 2000; i.e. a difference of -2.9 (95% confidence intervals, -3.5 to -2.4). ...
The patients were followed for a further 9 months. Mean number of ARTIs decreased from 8.2 +/- 2.1 per worker in 1999 to 5.3 +/- 2.9 …
Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels.
Del-Río-Navarro BE, Luis Sienra-Monge JJ, Berber A, Torres-Alcántara S, Avila-Castañón L, Gómez-Barreto D. Del-Río-Navarro BE, et al. Among authors: berber a. Allergol Immunopathol (Madr). 2003 Jan-Feb;31(1):7-13. doi: 10.1016/s0301-0546(03)79158-7. Allergol Immunopathol (Madr). 2003. PMID: 12573204 Clinical Trial.
METHODS: This was a randomized, double-blind, placebo-controlled clinical trial. Patients of ages three to six years, having three or more documented ARTIs during the last six months with subnormal IgG subclass levels were included. ...
METHODS: This was a randomized, double-blind, placebo-controlled clinical trial. Patients of ages three to six years, having three or …
Gutiérrez-Tarango MD, Berber A. Gutiérrez-Tarango MD, et al. Among authors: berber a. Clin Drug Investig. 1997;13(2):76-84. doi: 10.2165/00044011-199713020-00003. Clin Drug Investig. 1997. PMID: 18370454
Compilation and meta-analysis of randomized placebo-controlled clinical trials on the prevention of respiratory tract infections in children using immunostimulants.
Berber A, Del-Rio-Navarro B. Berber A, et al. J Investig Allergol Clin Immunol. 2001;11(4):235-46. J Investig Allergol Clin Immunol. 2001. PMID: 11908811
OBJECTIVES: To compile the findings of the randomized, placebo-controlled trials (RCTs) on the prevention of acute respiratory tract infections (ARTIs) in children using immunostimulants, and to perform a meta-analysis. ...We abstracted the number of ARTIs, and a on …
OBJECTIVES: To compile the findings of the randomized, placebo-controlled trials (RCTs) on the prevention of acute respiratory tract infecti …
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A. Fanghänel G, et al. Among authors: berber a. Int J Obes Relat Metab Disord. 2001 May;25(5):741-7. doi: 10.1038/sj.ijo.0801592. Int J Obes Relat Metab Disord. 2001. PMID: 11360159 Clinical Trial.
To evaluate the effect of Sibutramine 10 mg daily in patients who were on a diet for 6 months. DESIGN: After a double-blind, placebo-controlled, parallel, prospective phase for 6 months, the treatments were crossed over and the patients continued in double-blind obs …
To evaluate the effect of Sibutramine 10 mg daily in patients who were on a diet for 6 months. DESIGN: After a double-blind, p …
71 results
Jump to page
Feedback